Mural Oncology plc Files 8-K
| Field | Detail |
|---|---|
| Company | Mural Oncology PLC |
| Form Type | 8-K |
| Filed Date | Oct 24, 2025 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.01 M |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing
TL;DR
Mural Oncology plc filed an 8-K on 10/24/25 for shareholder votes and other events.
AI Summary
Mural Oncology plc filed an 8-K on October 24, 2025, reporting on matters submitted to a vote of security holders and other events. The company, formerly known as Pistachiovale Ltd and Mural Oncology Ltd, is incorporated in Ireland and has its principal executive offices in Dublin.
Why It Matters
This filing indicates that Mural Oncology plc is engaging in corporate actions requiring shareholder approval and is disclosing other significant events, which could impact investors' understanding of the company's governance and operations.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not contain information suggesting immediate or significant risk.
Key Numbers
- 001-41837 — SEC File Number (Identifies the company's filing history with the SEC.)
- 98-1748617 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- Mural Oncology plc (company) — Registrant
- Pistachiovale Ltd (company) — Former company name
- Mural Oncology Ltd (company) — Former company name
- Ireland (location) — Jurisdiction of incorporation
- Dublin (location) — City of principal executive offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of these matters are not provided in the excerpt.
What were the 'Other Events' reported in the 8-K?
The filing lists 'Other Events' as a category, but the specific nature of these events is not detailed in the provided text.
When was Mural Oncology plc incorporated?
The filing states the company is incorporated in Ireland, but the exact date of incorporation is not specified in this excerpt.
What is the company's principal executive office address?
The principal executive offices are located at 10 Earlsfort Terrace, Dublin 2, D02 T380, Ireland.
What was the company's previous name before Mural Oncology Ltd?
The company was formerly known as Pistachiovale Ltd before changing its name to Mural Oncology Ltd on March 29, 2023.
Filing Stats: 1,917 words · 8 min read · ~6 pages · Grade level 14.6 · Accepted 2025-10-24 16:35:09
Key Financial Figures
- $0.01 M — istered Ordinary Shares, nominal value $0.01 MURA The Nasdaq Global Market Indicate
Filing Documents
- d228748d8k.htm (8-K) — 44KB
- 0001193125-25-250044.txt ( ) — 160KB
- mura-20251024.xsd (EX-101.SCH) — 3KB
- mura-20251024_lab.xml (EX-101.LAB) — 17KB
- mura-20251024_pre.xml (EX-101.PRE) — 11KB
- d228748d8k_htm.xml (XML) — 4KB
From the Filing
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 24, 2025 Mural Oncology plc (Exact name of Registrant as Specified in Its Charter) Ireland 001-41837 98-1748617 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 10 Earlsfort Terrace Dublin 2 , D02 T380 , Ireland Not Applicable (Address of Principal Executive Offices) (Zip Code) Registrant's Telephone Number, Including Area Code: + 353 - 1-905-8020 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary Shares, nominal value $0.01 MURA The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item5.07. Submission of Matters to a Vote of Security Holders. On October 24, 2025, Mural Oncology plc, a public limited company organized under the laws of Ireland (the "Company"), held a special meeting of shareholders convened pursuant to section 450(1) of the Irish Companies Act 2014 (the "Scheme Meeting") and an extraordinary general meeting of shareholders (the "EGM"), in each case relating to the proposed acquisition (the "Acquisition") of the entire issued and to be issued share capital of the Company by XRA 5 Corp. ("Sub"), a wholly-owned subsidiary of XOMA Royalty Corporation ("XOMA Royalty"). The Acquisition is to be effected by means of a "scheme of arrangement" under Irish law (the "Scheme of Arrangement"), pursuant to the Transaction Agreement, dated August 20, 2025, among the Company, XOMA Royalty and Sub. Below are the voting results for the proposals submitted to the Company's shareholders for a vote at the Scheme Meeting and the EGM. Scheme Meeting PROPOSAL 1 : That the Scheme in its original form or with or subject to any modification(s), addition(s) or condition(s) approved or imposed by the Irish High Court be agreed to. The Company's shareholders approved Proposal 1 at the Scheme Meeting with the following voting results: For Against Abstain Broker Non-Votes 10,103,706 81,149 52,031 — In addition, of the 9 shareholders of record voting on the proposal, 8 shareholders, or 99.20% of those voting, voted in favor of the proposal and 1 shareholder, or 0.79% of those voting, voted against the proposal . The votes cast in favor of Proposal 1 represented a majority in number of the shareholders of record present and voting, either in person or by proxy, and at least 75% of the value of the shares voted at the meeting, either in person or by proxy. PROPOSAL 2 : The proposal to approve any motion by the Chair to adjourn the Scheme Meeting, or any adjournments thereof, to another time and place if necessary or appropriate to solicit additional proxies if there are insufficient votes at the time of the Scheme Meeting to approve the Scheme of Arrangement was not presented to the shareholders at the Scheme Meeting, as there were sufficient votes to approve Proposal 1. Extraordinary General Meeting PROPOSAL 1 : To approve the Scheme of Arrangement in its original form or with or subject to any modification(s), addition(s) or condition(s) approved or imposed by the Irish High Court and authorize the directors of the Company to take all such actions as they consider necessary or appropriate for carrying the Scheme of Arrangement into effect. The Company's shareholders approved Proposal 1 at the EGM with the following voting results: For Against Abstain Broker Non-Votes 10,607,228 89,435 13,056 — PROPOSAL 2 : To approve an amendment to the articles of association of the Company so that any ordinary shares of the Co